WELLESLEY HILLS, Mass., Sept. 2 /PRNewswire/ -- Joseph F. Finn, Jr., C.P.A. ("Finn"), Assignee of the assets of Spherics, Inc. ("Spherics") for the benefit of creditors, announced today that all pharmaceutical intellectual property will be sold at a sealed bid auction on October 10, 2008.
With SRx-503, Spherics has developed an improved version of a first and second line treatment for Parkinson's disease. Current global sales exceed $700 million (approx. $600 million US only), despite a severe side-effect profile (including motor fluctuations and GI and CNS AE's) and compliance issues (3x daily dosing). SRx-503 maintains a more stable release profile, bypasses the stomach to alleviate GI side effects and requires dosing only once daily.
Persons interested in bidding must sign a Confidentiality Agreement ("CA") obtained from Finn's office -- firstname.lastname@example.org or 781-237-8840. They will then receive a bid package and access to the Spherics electronic data room.
Spherics has built a strong intellectual property position around its drug delivery technologies and products. The Company has a broad range of issued US and international patents that they have applied to their four central nervous system products. These patents cover polyanhydride-based bioadhesive polymers and nanotechnology (PIN). In addition to these issued patents, Spherics has filed numerous applications covering compositions of matters of its proprietary polymers (SPHEROMERS), novel oral delivery systems (including BIOGIT, BIOROD and PIN), manufacturing methods, methods of use, formulations and product compositions.
About Joseph F. Finn, Jr., C.P.A.
Joseph F. Finn, Jr., is the founding partner of the firm, Finn, Warnke
& Gayton, Certified Public Accountants of Wellesley Hills, Massachusetts.
He works primarily in the area of management consulting for distressed
enterprises, bankruptcy account
Copyright©2008 PR Newswire.
All rights reserved